Skip to main content
Clinical Epigenetics logoLink to Clinical Epigenetics
. 2024 Aug 14;16:106. doi: 10.1186/s13148-024-01723-w

Mendelian randomization implicates causal association between epigenetic age acceleration and age-related eye diseases or glaucoma endophenotypes

Jiawei Chen 1,2, Xiang-Ling Yuan 1,3, Xiaoyu Zhou 2,4, Jiahao Xu 2,4, Xinyue Zhang 2,4, Xuanchu Duan 1,2,4,
PMCID: PMC11325616  PMID: 39143611

Abstract

Background

Age-related eye diseases (AREDs) have become increasingly prevalent with the aging population, serving as the leading causes of visual impairment worldwide. Epigenetic clocks are generated based on DNA methylation (DNAm) levels and are considered one of the most promising predictors of biological age. This study aimed to investigate the bidirectional causal association between epigenetic clocks and common AREDs or glaucoma endophenotypes.

Methods

Instrumental variables for epigenetic clocks, AREDs, and glaucoma endophenotypes were obtained from corresponding genome-wide association study data of European descent. Bidirectional two-sample Mendelian randomization (MR) was employed to explore the causal relationship between epigenetic clocks and AREDs or glaucoma endophenotypes. Multivariable MR (MVMR) was used to determine whether glaucoma endophenotypes mediated the association of epigenetic clocks with glaucoma. Multiple sensitivity analyses were conducted to confirm the robustness of MR estimates.

Results

The results showed that an increased intrinsic epigenetic age acceleration (HorvathAge) was significantly associated with an increased risk of primary open-angle glaucoma (OR = 1.04, 95% CI 1.02 to 1.06, P = 6.1E−04). The epigenetic age acceleration (EEA) of HannumAge was related to a decreased risk of primary angle-closure glaucoma (OR = 0.92, 95% CI 0.86 to 0.99, P = 0.035). Reverse MR analysis showed that age-related cataract was linked to decreased HannumAge (β = −0.190 year, 95% CI −0.374 to −0.008, P = 0.041). The EEA of HannumAge (β = −0.85 μm, 95% CI −1.57 to −0.14, P = 0.019) and HorvathAge (β = −0.63 μm, 95% CI −1.18 to −0.08, P = 0.024) were associated with decreased central corneal thickness (CCT). PhenoAge was related to an increased retinal nerve fiber layer thickness (β = 0.06 μm, 95% CI 0.01 to 0.11, P = 0.027). MVMR analysis found no mediation effect of CCT in the association of HannumAge and HorvathAge with glaucoma. DNAm-based granulocyte proportions were significantly associated with presbyopia, rhegmatogenous retinal detachment, and intraocular pressure (P < 0.05). DNAm-based plasminogen activator inhibitor-1 levels were significantly related to age-related macular degeneration and intraocular pressure (P < 0.05).

Conclusion

The present study revealed a causal association between epigenetic clocks and AREDs. More research is warranted to clarify the potential mechanisms of the biological aging process in AREDs.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13148-024-01723-w.

Keywords: Glaucoma, Central corneal thickness, Age-related cataract, Biological aging, Epigenetic clock, Mendelian randomization

Introduction

Advanced aging is an important risk factor for a variety of common eye diseases that are collectively referred to as age-related eye diseases (AREDs), including glaucoma, age-related macular degeneration (AMD), age-related cataract (ARC), presbyopia, diabetic retinopathy (DR), rhegmatogenous retinal detachment (RRD), and retinal vascular occlusion (RVO) [1]. As the global population ages, AREDs are becoming increasingly prevalent, seriously threatening visual health around the world. It was projected that 587.6 million people would suffer from moderate and severe vision impairment (visual acuity < 6/18 but > 3/60 in the better eye), and 114.6 million people would be blind (visual acuity < 3/60) in 2050 globally [2]. Cataract and uncorrected refractive error were the two main global causes of avoidable blindness, whereas glaucoma, AMD, and DR were the leading global causes of irreversible blindness in people aged 50 years and older in 2020 [3]. Although natural aging seems necessary for AREDs development, many elderly people never develop the diseases in their entire lives, indicating the various ages at disease onset [4]. Individuals with the same chronological age can have inter-individual differences in the risk of AREDs due to different aging rates. Therefore, biological age may be a more effective predictor of disease risk associated with aging. Becker et al. thought that chronological age was an independent risk factor for AREDs, whereas biological age was the main driver of the diseases, which can be accelerated by environmental factors, lifestyle, and genetic variants [4].

Several common biomarkers were used to predict biological age, including epigenetic clocks, telomere length, transcriptomics, proteomics, metabolomics, and composite biomarker predictors [5]. Among them, the epigenetic clock, also known as DNA methylation age (DNAmAge), is regarded as one of the most promising predictors [6]. Epigenetic clocks measure the DNA methylation (DNAm) levels at specific cytosine-phosphate-guanine (CpG) loci, combined with regression analysis to evaluate biological age status. The first generation of epigenetic clocks comprises DNAm HorvathAge [7] and HannumAge [8], which are trained on chronological age. HorvathAge is the most widely used epigenetic clock tool, and it is also the first multi-tissue, all lifespans biological age estimator that utilizes 353 age-related CpGs assessed in 51 different tissues and cell types [6, 7]. Intrinsic epigenetic age acceleration (IEAA) is a derivative of the Horvath clock, which adjusts blood cell composition, and is considered a biomarker of cell-intrinsic aging [9]. HannumAge measures extrinsic aging based on 71 age-related CpGs from whole blood samples of adults [8, 9]. It can accurately predict biological age using blood samples collected from adults but has poor accuracy in non-blood tissues or from children [6]. The second generation of epigenetic clocks, including DNAm PhenoAge and GrimAge, are trained on a composite of biomarkers and, have an excellent ability to predict the morbidity and mortality risks of individuals [10, 11]. PhenoAge is based on 513 age-related CPGs from multiple clinical biomarkers and is strongly associated with mortality and behavioral lifestyle [10]. GrimAge was derived from 7 DNAm-based plasma protein markers associated with diseases, health, and smoking, resulting in better performance in predicting lifespan than other estimators [6, 11]. Epigenetic age acceleration (EAA) was used to describe the difference in DNAmAge from chronological age, reflecting the aging rate of individual organisms [12]. Although senescence is associated with AREDs, no research regarding the association between EAA or epigenetic clocks and AREDs has been conducted.

Mendelian randomization (MR) is an effective approach to investigate the potential causality between exposure factors and outcome phenotypes and has been widely applied to affirm the causal effect of diseases or risk factors on outcomes of interest. Based on the theory of random genetic variant allocation, MR analysis makes use of single nucleotide polymorphisms (SNPs) as instrumental variables (IVs) to derive causal estimations between two traits not affected by confounding effects and reverse causation [13]. Therefore, this study aimed to determine the causal association between epigenetic clocks and the risk of AREDs or glaucoma endophenotypes using bidirectional two-sample Mendelian randomization (TSMR) combined with multivariable Mendelian randomization (MVMR).

Methods

Study design

An outline of the study design and principles is shown in Fig. 1. Initially, we employed TSMR to evaluate the genetically predicted causality between epigenetic clocks and AREDs. In the forward TSMR analysis, epigenetic clocks were used as “exposure” variables and ocular diseases were used as “outcome” variables. Reverse TSMR analysis was performed using ocular diseases as “exposure” variables and epigenetic clocks as “outcome” variables. Then, we further explored the causal association between epigenetic clocks and glaucoma endophenotypes since a significant relationship was identified between epigenetic aging and glaucoma. MVMR was applied to investigate the mediation effect of glaucoma endophenotypes on the association of epigenetic clocks with glaucoma. MR analysis relies on three key assumptions as follows [14]: (1) Relevance assumption: IVs must be strongly associated with exposure phenotype. (2) Independence assumption: IVs should be independent of potential confounders. (3) Exclusion restriction assumption: IVs solely affect outcomes through predicted exposure.

Fig. 1.

Fig. 1

The overview of the study design and principles of the present MR analysis. GCP, DNAm-based granulocyte proportions; IEAA, intrinsic epigenetic age acceleration; PAI-1, DNAm-based plasminogen activator inhibitor-1 levels; AMD, age-related macular degeneration; DR, diabetic retinopathy; PACG, primary angle-closure glaucoma; POAG, primary open-angle glaucoma; RRD, rhegmatogenous retinal detachment; RVO, retinal vascular occlusion; ARC, age-related cataract; CCT, central corneal thickness; IOP, intraocular pressure; mRNFL, macular retinal nerve fiber layer thickness; VCDR, vertical cup-to-disk ratio

Data sources

Table 1 summarizes the data sources for all phenotypes in the MR analysis. The genome-wide association studies (GWAS) data for four epigenetic clocks, including PhenoAge, GrimAge, HannumAge, and IEAA (HorvathAge), were obtained from a recent meta-analysis comprising a total of 34,710 European ancestry participants from 28 cohorts [15]. This GWAS meta-analysis successfully identified 137 genetic variants representing DNA methylation biomarkers of biological aging. We also included two important DNA methylation-based biomarkers, namely DNA methylation proxies for granulocyte proportions (GCP) and plasminogen activator inhibitor-1 (PAI-1) levels [15]. Neutrophils, the main components of granulocytes, are considered pathogenic mediators and biomarkers of AREDs [16]. Previous studies have shown that PAI-1 might contribute to the pathogenesis of glaucoma, AMD, and DR [17, 18].

Table 1.

Data sources for MR analyses in this study

Phenotypes Cases Controls Sample size Ancestry Source Pubmed ID
Epigenetic age acceleration 34,710 European Edinburgh DataShare 34187551
Age-related macular degeneration 9721 381,339 391,060 European FinnGen study R10 36653562
Age-related cataract 65,235 341,546 406,781
Presbyopia 1597 394,028 395,625
Primary angle-closure glaucoma 1307 391,275 392,582
Primary open-angle glaucoma 8530 391,275 399,805
Rhegmatogenous retinal detachment 4024 376,650 380,674
Retinal vascular occlusion 3635 376,650 380,285
Diabetic retinopathy 10,413 308,633 319,046 European FinnGen study R9 36653562
Central corneal thickness 16,204 European International Glaucoma Genetic Consortium 31798171
Intraocular pressure 31,269
Vertical cup-to-disk ratio 25,180
Macular retinal nerve fiber layer thickness 31,434 European UK biobank 33979322

Eight common AREDs, including AMD, ARC, presbyopia, primary angle-closure glaucoma (PACG), primary open-angle glaucoma (POAG), RRD, RVO, and DR, were considered in this MR study. The genetic instruments for these eight ocular diseases (AMD: 9721 cases, and 381,339 controls; ARC: 65,235 cases, and 341,546 controls; presbyopia: 1597 cases, and 394,028 controls; PACG: 1,307 cases, and 391,275 controls; POAG: 8530 cases, and 391,275 controls; RRD: 4024 cases, and 376,650 controls; RVO: 3635 cases, and 376,650 controls; DR, 10,413 cases, and 308,633 controls) were acquired from the FinnGen study based on European-descent individuals [19]. The FinnGen study is a large-scale genomics initiative that has analyzed over 500,000 Finnish biobank samples and correlated genetic variations with health data to elucidate disease mechanisms and predispositions [19].

Central corneal thickness (CCT), intraocular pressure (IOP), vertical cup-to-disk ratio (VCDR), and macular retinal nerve fiber layer (mRNFL) thickness are the four main endophenotypes of glaucoma. The summary data for CCT (16,204 individuals), IOP (31,269 individuals), and VCDR (25,180 individuals) were collected from a multi-trait GWAS study involving European ancestry participants via the GWAS Catalog (https://www.ebi.ac.uk/gwas/) [20]. The genetic instruments for mRNFL were extracted from a GWAS study of inner retinal morphology based on optical coherence tomography (OCT) images of 31,434 European ancestry participants from the UK Biobank [21].

Selection of instrumental variables

To meet the relevance assumption, SNPs associated with each exposure at genome-wide significance (P < 5 × 10–8) level were extracted as IVs. Due to the lack of effective IVs, the threshold of the P value was loosened to 5 × 10–6 for the four epigenetic clocks, and 1 × 10–6 for GCP and PAI-1, similar to prior studies [22, 23]. For the same reason, the P value threshold for IVs selection was set at 5 × 10–7 for DR, CCT, and IOP, 5 × 10–6 for AMD, presbyopia, and RD, as well as 5 × 10–5 for PACG and RVO. We preserved the SNPs without linkage disequilibrium (LD) using criteria of r2 < 0.001 and clumping distance > 10 Mb based on the European 1000 Genomes for subsequent analysis. To filter high-quality IVs, we excluded SNPs with potentially low confidence (MAF < 0.01), weak instrumental variables (F-statistics < 10), ambiguous and palindromic SNPs, or SNPs potentially associated with outcome (P < 0.01) [24]. For each single variant, the F-statistics was calculated using the formula F =β2SE2, and the proportion of variance in the exposure explained by the genetic variants (R2) was calculated using the formula R2=2×MAF×(1-MAF)×β2, where β is the genetic association with exposure (SE, standard error for β; MAF, minor allele frequency) [25, 26]. In addition, Steiger filtering was performed to ensure the correct direction from exposure to the outcome [27]. We searched the Ensembl database (https://www.ensembl.org/) and deleted the SNPs associated with underlying confounding risk factors (including myopia, diabetes, hypertension, smoking, and body mass index) affecting epigenetic clocks and AREDs. Proxy SNPs were not used to avoid bringing in unpredicted bias in this study [28].

Mendelian randomization analysis

For the TSMR analysis, we used the inverse-variance weighted (IVW) with a multiplicative random-effects model as the primary approach to determine the causal associations between epigenetic clocks and AREDs or glaucoma endophenotypes. The MR-pleiotropy residual sum and outlier (MR-PRESSO), MR-Egger, and Weighted median served as supplementary methods to evaluate the robustness of the MR estimations. The direct effect (βa) of epigenetic clocks on CCT was derived from TSMR. MVMR-IVW was performed to assess the direct effect (βb) of CCT on glaucoma. The mediation effect was calculated using the formula of βmed=βa×βb, where SEmed=βa2×SEb2+βb2×SEa2, Zmed=βmedSEmed, and Pmed were derived from the Z score table [29].

Cochran’s Q test was conducted to assess heterogeneity among SNPs using the IVW and MR-Egger methods [30]. The random-effects model of the IVW method can address the effect of heterogeneity and accurately make causal estimations [31]. Horizontal pleiotropy of IVs was detected using MR-Egger intercept and MR-PRESSO Global test. Significant horizontal pleiotropy indicates the existence of an alternative pathway that allows IVs of exposure to affect the outcome, which violates the exclusion restriction assumption of MR analysis. Additionally, scatter plots, funnel plots, and leave-one-out analyses were used to visualize potential heterogeneity and pleiotropy. The statistical power was calculated using an online calculator (https://sb452.shinyapps.io/power/) [32].

Statistical analysis

A two-sided significance threshold of P < 0.05 was applied to all statistical analyses. All MR analyses were conducted using the “TwoSampleMR” package (Version 0.6.3) [33], “MendelianRandomization” package (Version 0.9.0) [34], or “MVMR” package (Version 0.4) [35] in R software (Version 4.3.2; https:// www.R-project.org/).

Results

Instrumental variables selection

After the rigorous filtering procedure, we screened 41, 56, 35, 27, 32, and 36 qualified SNPs as IVs for HannumAge (F-statistics range 21 to 99), IEAA (F-statistics range 21 to 240), PhenoAge (F-statistics range 21 to 89), GrimAge (F-statistics range 21 to 45), GCP (F-statistics range 18 to 76), and PAI-1 (F-statistics range 20 to 163), respectively. For ocular diseases, 64, 32, 23, 85, 46, 16, 84, and 40 qualified SNPs were selected as IVs for AMD (F-statistics range 21 to 1008), DR (F-statistics range 26 to 1283), presbyopia (F-statistics range 21 to 26), PACG (F-statistics range 17 to 28), POAG (F-statistics range 30 to 200), RRD (F-statistics range 21 to 40), RVO (F-statistics range 16 to 32), and ARC (F-statistics range 30 to 257), respectively. For glaucoma endophenotypes, 37, 20, 28, and 22 qualified SNPs were chosen as IVs for CCT (F-statistics range 26 to 257), IOP (F-statistics range 25 to 75), mRNFL (F-statistics range 30 to 115), and VCDR (F-statistics range 29 to 207), respectively. The F-statistics of all IVs were > 10, indicating that the MR estimations were not biased by weak instrumental variables.

Causal association between epigenetic aging and age-related eye diseases

Forward TSMR analysis showed that genetically predicted HannumAge was significantly associated with PACG (IVW: odds ratio [OR] = 0.92, 95% confidence interval [CI] 0.86 to 0.99, P = 0.035; Table 2). An increase in genetically predicted IEAA was significantly associated with an increased risk of POAG (IVW: OR = 1.04, 95% CI 1.02 to 1.06, P = 6.1E-04). Increased DNAm-based PAI-1 levels was significantly associated with an increased risk of AMD (IVW: OR = 1.00006, 95% CI 1.000002 to 1.0001, P = 0.042). The DNAm-based estimate of GCP was significantly associated with presbyopia (IVW: OR = 0.010, 95% CI 0.0002 to 0.522, P = 0.022) and RRD (IVW: OR = 26.64, 95% CI 2.70 to 263.05, P = 0.005). The reverse TSMR analysis revealed that genetic predisposition to ARC was significantly associated with an increase in HannumAge (IVW: β = −0.190, 95% CI −0.374 to −0.008, P = 0.041). We did not find any significant associations between epigenetic clocks and other AREDs (Fig. 2, Tables S1 and S4).

Table 2.

Significant causal associations between epigenetic age acceleration and age-related eye diseases estimated using bidirectional TSMR

Exposure Outcome SNPs Method OR (95% CI) P PQ PInt PG Power (%)
HannumAge PACG 41 IVW 0.92 (0.86 to 0.99) 0.035 0.510 0.020 0.502 65.0
MR-Egger 0.75 (0.62 to 0.90) 0.004
MR-PRESSO 0.92 (0.86 to 0.99) 0.039
WM 0.90 (0.81 to 1.01) 0.068
IEAA POAG 54 IVW 1.04 (1.02 to 1.06) 6.1E-04 0.732 0.300 0.743 96.5
MR-Egger 1.02 (0.97 to 1.06) 0.521
MR-PRESSO 1.04 (1.02 to 1.06) 5.7E-04
WM 1.03 (0.996 to 1.060) 0.084
PAI-1 AMD 33 IVW 1.00006 (1.000002 to 1.0001) 0.042 0.291 0.510 0.335 69.3
MR-Egger 1.00007 (1.000005 to 1.0001) 0.042
MR-PRESSO 1.00006 (1.000002 to 1.0001) 0.050
WM 1.00004 (0.999959 to 1.0001) 0.320
GCP Presbyopia 27 IVW 0.010 (0.0002 to 0.522) 0.022 0.313 0.211 0.341 70.6
MR-Egger 0.00003 (1.69E-09 to 0.494) 0.046
MR-PRESSO 0.010 (0.0002 to 0.522) 0.031
WM 0.003 (0.00001 to 0.603) 0.032
GCP RRD 29 IVW 26.64 (2.70 to 263.05) 0.005 0.564 0.617 0.613 82.9
MR-Egger 6.70 (0.02 to 2256.62) 0.527
MR-PRESSO 26.64 (2.91 to 243.72) 0.007
WM 22.27 (0.83 to 598.38) 0.065
ARC HannumAge 31 IVW 0.83 (0.69 to 0.99) 0.041 0.988 0.708 0.988 100
MR-Egger 0.75 (0.45 to 1.26) 0.289
MR-PRESSO 0.83 (0.72 to 0.94) 0.008
WM 0.86 (0.66 to 1.12) 0.259

AMD, age-related macular degeneration; PACG, primary angle-closure glaucoma; POAG, primary open-angle glaucoma; RRD, rhegmatogenous retinal detachment; ARC, age-related cataract; PAI-1, DNAm-based plasminogen activator inhibitor-1 levels; GCP, DNAm-based granulocyte proportions; IEAA, intrinsic epigenetic age acceleration; TSMR, two-sample Mendelian randomization; IVW, inverse-variance weighted; MR-PRESSO, Mendelian randomization pleiotropy residual sum and outlier; WM, weighted median; OR, odds ratio; 95% CI, 95% confidence interval; PQ was the P value derived from Cochran’s Q test using IVW method. PInt was the P value derived from MR-Egger intercept. PG was the P value derived from MR-PRESSO global test. P < 0.05 was considered as statistically significant

Fig. 2.

Fig. 2

MR estimated the causal association between epigenetic age acceleration and age-related eye diseases using the inverse-variance weighted method. GCP, DNAm-based granulocyte proportions; IEAA, intrinsic epigenetic age acceleration; PAI-1, DNAm-based plasminogen activator inhibitor-1 levels; AMD, age-related macular degeneration; DR, diabetic retinopathy; PACG, primary angle-closure glaucoma; POAG, primary open-angle glaucoma; RRD, rhegmatogenous retinal detachment; RVO, retinal vascular occlusion; ARC, age-related cataract; P < 0.05 was considered statistically significant

We had high statistical powers (power > 80%) for the causal estimations from IEAA on POAG, GCP on RRD, and ARC on HannumAge, but moderate statistical powers were shown for the causal estimations from HannumAge on PACG, PAI-1 on AMD, and GCP on presbyopia (Table 2). Although the MR-Egger intercept indicated potential pleiotropy in the causality from HannumAge on PACG, this could not be confirmed by the MR-PRESSO Global test. No significant heterogeneity or pleiotropy affected the other significant associations between epigenetic clocks and ocular diseases.

Causal association between epigenetic aging and glaucoma endophenotypes

In the forward TSMR analysis, genetic liability for increased HannumAge (IVW: β = −0.85 μm, 95% CI −1.57 to −0.14, P = 0.019) and IEAA (IVW: β = -0.63μm, 95% CI -1.18 to -0.08, P = 0.024) was significantly associated with decreased CCT (Table 3). Genetically predicted PhenoAge was significantly associated with mRNFL (IVW: β = 0.06 μm, 95% CI 0.01 to 0.11, P = 0.027). Genetic liability for the DNAm-based estimate of GCP (IVW: β = −3.03 mmHg, 95% CI −5.86 to −0.20, P = 0.036) and PAI-1 (IVW: β = 0.0001mmHg, 95% CI 0.00002 to 0.0002, P = 0.015) was significantly associated with IOP. Reverse TSMR analysis showed that genetically predicted IOP was significantly associated with PAI-1 (IVW: β = 0.26, 95% CI 0.01 to 0.50, P = 0.041). No significant associations between epigenetic clocks and other glaucoma endophenotypes were observed (Fig. 3, Tables S7 and S10). All statistical powers of the significant causal estimations between epigenetic clocks and glaucoma endophenotypes were 100%. We found no heterogeneity or pleiotropy in the significant associations between epigenetic clocks and glaucoma endophenotypes (Table 3).

Table 3.

Significant causal associations between epigenetic age acceleration and glaucoma endophenotypes estimated using bidirectional TSMR

Exposure Outcome SNPs Method Beta (95% CI) P PQ PInt PG Power (%)
HannumAge CCT 41 IVW −0.85 (−1.57 to −0.14) 0.019 0.900 0.343 0.906 100
MR-Egger −1.65 (−3.43 to 0.13) 0.077
MR-PRESSO −0.85 (−1.46 to −0.24) 0.009
WM −0.86 (−1.89 to 0.17) 0.101
IEAA CCT 55 IVW −0.63 (−1.18 to −0.08) 0.024 0.694 0.781 0.693 100
MR-Egger −0.46 (−1.74 to 0.82) 0.480
MR-PRESSO −0.63 (−1.15 to −0.11) 0.021
WM −0.49 (−1.28 to 0.29) 0.218
PhenoAge mRNFL 34 IVW 0.06 (0.01 to 0.11) 0.027 0.692 0.153 0.698 100
MR-Egger −0.02 (−0.13 to 0.10) 0.770
MR-PRESSO 0.06 (0.01 to 0.11) 0.023
WM 0.05 (−0.03 to 0.13) 0.200
GCP IOP 30 IVW −3.03 (−5.86 to −0.20) 0.036 0.210 0.417 0.200 100
MR-Egger −5.93 (−13.40 to 1.53) 0.130
MR-PRESSO −3.03 (−5.86 to −0.20) 0.044
WM −2.97 (−6.99 to 1.05) 0.147
PAI-1 IOP 36 IVW 0.0001 (0.00002 to 0.0002) 0.015 0.496 0.753 0.523 100
MR-Egger 0.0001 (0.00001 to 0.0002) 0.042
MR-PRESSO 0.0001 (0.00002 to 0.0002) 0.019
WM 0.0001 (−0.00005 to 0.0002) 0.259
IOP PAI-1 18 IVW 0.26 (0.01 to 0.50) 0.041 0.326 0.767 0.317 100
MR-Egger 0.40 (−0.56 to 1.36) 0.429
MR-PRESSO 0.26 (0.01 to 0.50) 0.057
WM 0.20 (−0.14 to 0.53) 0.257

CCT, central corneal thickness; IOP, intraocular pressure; mRNFL, macular retinal nerve fiber layer thickness; PAI-1, DNAm-based plasminogen activator inhibitor-1 levels; GCP, DNAm-based granulocyte proportions; IEAA, intrinsic epigenetic age acceleration; TSMR, two-sample Mendelian randomization; IVW, inverse-variance weighted; MR-PRESSO, Mendelian randomization pleiotropy residual sum and outlier; WM, weighted median; OR, odds ratio; 95% CI, 95% confidence interval; PQ was the P value derived from Cochran’s Q test using IVW method. PInt was the P value derived from MR-Egger intercept. PG was the P value derived from MR-PRESSO global test. P < 0.05 was considered as statistically significant

Fig. 3.

Fig. 3

MR estimated the causal association between epigenetic age acceleration and glaucoma endophenotypes using the inverse-variance weighted method. GCP, DNAm-based granulocyte proportions; IEAA, intrinsic epigenetic age acceleration; PAI-1, DNAm-based plasminogen activator inhibitor-1 levels; CCT, central corneal thickness; IOP, intraocular pressure; mRNFL, macular retinal nerve fiber layer thickness; VCDR, vertical cup-to-disk ratio; 95% CI, 95% confidence interval; P < 0.05 was considered statistically significant

Mediation effect of glaucoma endophenotypes

MVMR analysis showed that the association of HannumAge with PACG lost statistical significance after adjusting for CCT (Table 4). Genetically predicted IEAA was still significantly associated with POAG after adjusting for CCT (IVW: OR = 0.967, 95% CI 0.939 to 0.997, P = 0.029). Heterogeneity was observed in the MVMR analysis of IEAA, CCT, and POAG. No significant pleiotropy was observed in all MVMR analyses. However, we found no significant mediation effect of CCT on the association between epigenetic clocks and glaucoma (Table 5).

Table 4.

Casual association between epigenetic age acceleration and glaucoma adjusting CCT using multivariable MR

Exposure Outcome SNPs Method OR (95% CI) P F-statistic Heterogeneity Pleiotropy
HannumAge PACG 79 IVW 0.997 (0.916 to 1.085) 0.941 15

Q = 98,

P = 0.051

Intercept = −0.0096,

se = 0.0085,

P = 0.259

MR-Egger 1.041 (0.93 to 1.166) 0.485
LASSO 0.991 (0.915 to 1.074) 0.827
CCT IVW 1.001 (0.996 to 1.006) 0.762 23
MR-Egger 1.001 (0.995 to 1.006) 0.843
LASSO 1.002 (0.997 to 1.007) 0.511
IEEA POAG 89 IVW 0.967 (0.939 to 0.997) 0.029 23

Q = 178,

P = 3.0E−08

Intercept = −0.0003,

se = 0.0044,

P = 0.947

MR-Egger 0.968 (0.927 to 1.011) 0.147
LASSO 0.974 (0.954 to 0.995) 0.017
CCT IVW 1.002 (0.999 to 1.005) 0.130 19
MR-Egger 1.002 (0.999 to 1.005) 0.132
LASSO 1.006 (1.004 to 1.009) 1.9E−06

PACG, primary angle-closure glaucoma; POAG, primary open-angle glaucoma; CCT, central corneal thickness; IEAA, intrinsic epigenetic age acceleration; IVW, inverse-variance weighted; MR, Mendelian randomization. P < 0.05 was considered as statistically significant

Table 5.

Mediation effect of central corneal thickness in the association between epigenetic age acceleration and glaucoma

Exposure Mediator Outcome Total effecta Direct effectb Mediation effect
Beta SE PIVW Beta SE PIVW Effect SE Pmed Proportion (%)
HannumAge CCT PACG −0.080 0.038 0.035 −0.003 0.043 0.941 −0.0007 0.0023 0.382 0.88
IEAA CCT POAG 0.037 0.011 6.10E−04 −0.033 0.015 0.029 −0.0014 0.0011 0.104 3.78

PACG, primary angle-closure glaucoma; POAG, primary open-angle glaucoma; CCT, central corneal thickness; IEAA, intrinsic epigenetic age acceleration; IVW, inverse-variance weighted; Pmed was derived from Z score table. P < 0.05 was considered as statistically significant

a. The causal effects of epigenetic aging on glaucoma derived from univariable two-sample MR analyses

b. The causal effects of epigenetic aging on glaucoma derived from multivariable MR analyses

Discussion

As one of the common and important AREDs, glaucoma is a group of optic neurodegenerative diseases associated with pathologically increased IOP [36]. Primary glaucoma can be classified as POAG and PACG according to the status of the anterior chamber angle when IOP is raised. It was projected that approximately 112 million people would suffer from glaucoma worldwide in 2040, including nearly 80 million POAG patients and 32 million PACG patients [37]. Advanced age is the second most critical risk factor for glaucoma in addition to IOP elevation. A meta-analysis showed that, with each decade increase in age beyond 40 years, the OR for POAG was 1.73 (95% CI 1.63–1.82) after adjusting for gender, habitation type, response rate, and year of study conducted [37], and the OR for PACG was 2.18 (95% CI 1.89–2.54) in Asia [38]. In the present study, we systemically investigated the bidirectional causal associations between genetically predicted epigenetic clocks and the eight most common AREDs, as well as four glaucoma endophenotypes. Our findings showed that genetically predicted IEAA was significantly associated with a higher risk of POAG, and genetically predicted EEA of HannumAge was significantly related to a lower risk of PACG. Genetically predicted EEA of HannumAge and IEAA were also significantly associated with decreased CCT. MR analysis showed significant bidirectional causality between genetically predicted PAI-1 and IOP. Based on a comprehensive literature search of Pubmed and Web of Science, this study is the first MR analysis coupled with large-scale GWAS data to comprehensively determine the causal relationship between epigenetic clocks and AREDs. The findings of our study suggested the contribution of genetically predicted DNAmAge on the risk of AREDs and the age-related changes of glaucomatous endophenotypes.

Our study revealed that the OR for POAG was 1.04 (95% CI 1.02–1.06) with each year increase in genetically predicted IEAA, which was equal to 1.48 (95% CI 1.22–1.79) with each decade increase in genetically predicted IEAA, highlighting the effect of cell-intrinsic aging on glaucoma. The accumulation of senescent cells is a basic physiological and pathological change during body aging. Many studies have indicated the critical contribution of cellular senescence to the development of glaucoma since increased levels of senescence biomarkers, such as senescence-associated beta-galactosidase (SA-β-gal), senescence-associated secretory phenotype [SASP, including interleukin-6 (IL-6), IL-1β, IL-8, transforming growth factor beta1 (TGF-β1) and vascular endothelial growth factor-α (VEGF-α)], and ungraded expression of senescence-associated genes (including p16INK4a, p21WAF-1, p53, and p15INK4b) were found in TM cells and retinal ganglion cells (RGCs) in patients with glaucoma [39]. Elevated IOP is in connection with the upregulation of p16INK4a and increased expression of SASP [40, 41]. In addition, age retinas are susceptible to high-IOP induced damages, such as loss of RGCs and functional changes [4, 42]. Elimination of senescent cells and knockout of senescence-associated genes have been proposed as effective therapeutic approaches for preventing RGCs death, alleviating structural damages, and improving visual function [40, 43, 44].

As an important biomarker of aging, DNA methylation has been suggested to be associated with glaucoma development by growing evidence. A higher level of DNA methylation was found in glaucomatous lamina cribrosa cells and TM cells [45, 46]. A DNA methylation study by Cai et al. revealed differential DNA methylation patterns in human Schlemm's canal endothelial cells with glaucoma and identified differentially methylated regions of glaucoma-related genes, including TBX3, TNXB1, DAXX, and PITX2 [47]. Wan et al. delineated the crucial effect of hypomethylation on growth differentiation factor 7 (GDF7) in aqueous humor outflow obstruction and confirmed that GDF7 neutralization therapy could effectively control IOP [48]. Reprograming age-associated epigenetic modifications has been shown to reverse vision loss in glaucoma mouse models and in aged mice [49]. In the present study, DNA methylation IEAA was significantly associated with an increased risk of POAG, suggesting that the epigenetic clock could be a potential predictor of glaucoma risk and detect retinal or optic damage in patients with glaucoma. Unexpectedly, the genetically predicted EEA of HannumAge was related to a decreased risk of PACG. HannumAge is a single-tissue (whole blood sample) DNAmAge estimator that reflects age-dependent changes in cell type composition [9]. Observational studies have suggested that changes in the composition of blood cells are involved in the pathogenesis and development of PACG. A higher red blood cell distribution width (RDW) was found in PACG patients, and an increased RDW was associated with the severity of PACG [50]. The neutrophil-to-lymphocyte ratio was significantly greater in the peripheral blood of patients with PACG than in the controls [51]. However, the causal association between the EEA of HannumAge and PACG should be interpreted with caution because potential pleiotropy was observed by the MR-Egger intercept but not the MR-PRESSO global test.

Evaluating the relationship between epigenetic clocks and glaucoma endophenotypes would help clarify the impact of epigenetic clocks on glaucoma. A thin cornea is considered an underlying risk factor for glaucoma [52]. Our analysis showed that the genetically predicted EEA of HannumAge and IEAA were significantly related to decreased CCT, possibly indicating an increased risk of glaucoma mediated by CCT. However, we did not observe any significant mediation effect of CCT on the causality from HannumAge on PACG, and IEAA on POAG. More studies are required to clarify the meaning of decreased CCT with aging in patients with glaucoma. RNFL thinning and enlarged VCDR are the direct signs of RGCs loss caused by IOP elevation [36]. An unexpected association was observed between the genetically predicted EEA of PhenoAge and increased mRNFL thickness in this study. Yet, it should be interpreted prudently due to the contrary effect direction estimated by MR-Egger. Retrospective studies have shown a significant decline in RNFL thickness with aging (range −0.20 μm to −0.70 μm per year) [5355]. This unexpectedly inconsistent finding between MR analysis and observational research should be addressed in future studies. A bidirectional causal association between increased DNAm-based PAI-1 levels and increased IOP was revealed by this MR analysis. Higher levels of DNAm-based PAI-1 were found to be associated with hypertension, diabetes, coronary heart disease, and early age at menopause, whereas lower levels were related to disease-free status and better physical functioning [11]. These findings suggest that high PAI-1 level could be a potential explanation for the association between systemic diseases and elevated IOP or glaucoma risk.

PAI-1 is the main substance that inhibits fibrinolytic activity in blood circulation, and an increase in PAI-1 levels can lead to a decrease in fibrinolytic activity, thus increasing the risk of thrombosis. However, we did not observe a significant association between genetically predicted PAI-1 and RVO. The annual incidence of AMD is 0.03% in people aged 55 to 59 years, increasing to 3.67% in people aged 90 years or older [56]. DNA methylation estimated PAI-1 level was related to an increased risk of AMD, but the OR was relatively small. This was consistent with the findings of previous studies showing that PAI-1 could induce the development of choroidal experimental neovascularization in AMD, suggesting a potential therapeutic approach of targeting PAI-1 in neovascular AMD [18]. DNA methylation estimated GCP was associated with a decreased risk of presbyopia in this study. Presbyopia is the result of the declined accommodation of the ciliary muscle and lens [57]. Our findings raise concerns about the effect of age-associated inflammation on the development of presbyopia. However, genetically predicted GCP was also associated with an increased risk of RRD, with a meaningful OR value, suggesting that age-associated inflammation greatly contributed to the development of RRD. Maidana et al. found that peripheral monocytes and neutrophils were responsible for photoreceptor degeneration in an experimental retinal detachment model, highlighting the important role of immune cell infiltration in the pathogenesis of retinal detachment [58].

There are inevitable limitations to our study. First, this study was based on summary GWAS data derived from European ancestry population, raising concerns over the generalizability of the findings to other ethnic populations. Second, although all four epigenetic clocks represent DNA methylation-based biological age, they did not show consistent results in the relationship with AREDs because they were trained using different approaches. There is currently a lack of an epigenetic clock that can accurately assess the biological age of ocular tissues. Finally, genetic variants can only explain a portion of the variability in epigenetic clocks and AREDs; thus, environmental factors and lifestyle should be considered when evaluating the complex interaction between DNAmAge and AREDs.

Conclusion

The present study demonstrated a causal association between accelerated epigenetic clocks, age-associated PAI-1 levels, GCP, and the risk of AREDs, as well as changes in glaucoma endophenotypes. More studies are required to elucidate the mechanisms underlying the biological aging effect on AREDs.

Supplementary Information

13148_2024_1723_MOESM1_ESM.pdf (2.4MB, pdf)

Additional file 1: Fig. S1. Scatter plots of significant MR estimations between epigenetic age acceleration and age-related eye diseases. (a) HannumAge on primary angle-closure glaucoma; (b) intrinsic epigenetic age acceleration on primary open-angle glaucoma; (c) DNAm-based plasminogen activator inhibitor-1 levels on age-related macular degeneration; (d) DNAm-based granulocyte proportions on presbyopia; (e) DNAm-based granulocyte proportions on rhegmatogenous retinal detachment; (f) age-related cataract on HannumAge. Fig. S2. Funnel plots of significant MR estimations between epigenetic age acceleration and age-related eye diseases. (a) HannumAge on primary angle-closure glaucoma; (b) intrinsic epigenetic age acceleration on primary open-angle glaucoma; (c) DNAm-based plasminogen activator inhibitor-1 levels on age-related macular degeneration; (d) DNAm-based granulocyte proportions on presbyopia; (e) DNAm-based granulocyte proportions on rhegmatogenous retinal detachment; (f) age-related cataract on HannumAge. Fig. S3. Leave-one-out plots of significant MR estimations between epigenetic age acceleration and age-related eye diseases. (a) HannumAge on primary angle-closure glaucoma; (b) intrinsic epigenetic age acceleration on primary open-angle glaucoma; (c) DNAm-based plasminogen activator inhibitor-1 levels on age-related macular degeneration; (d) DNAm-based granulocyte proportions on presbyopia; (e) DNAm-based granulocyte proportions on rhegmatogenous retinal detachment; (f) age-related cataract on HannumAge. Fig. S4. Scatter plots of significant MR estimations between epigenetic age acceleration and glaucoma endophenotypes. (a) HannumAge on central corneal thickness; (b) intrinsic epigenetic age acceleration on central corneal thickness; (c) PhenoAge on macular retinal nerve fiber layer thickness; (d) DNAm-based granulocyte proportions on intraocular pressure; (e) DNAm-based plasminogen activator inhibitor-1 levels on intraocular pressure; (f) intraocular pressure on DNAm-based plasminogen activator inhibitor-1 levels. Fig. S5. Funnel plots of significant MR estimations between epigenetic age acceleration and glaucoma endophenotypes. (a) HannumAge on central corneal thickness; (b) intrinsic epigenetic age acceleration on central corneal thickness; (c) PhenoAge on macular retinal nerve fiber layer thickness; (d) DNAm-based granulocyte proportions on intraocular pressure; (e) DNAm-based plasminogen activator inhibitor-1 levels on intraocular pressure; (f) intraocular pressure on DNAm-based plasminogen activator inhibitor-1 levels. Fig. S6. Leave-one-out plots of significant MR estimations between epigenetic age acceleration and glaucoma endophenotypes. (a) HannumAge on central corneal thickness; (b) intrinsic epigenetic age acceleration on central corneal thickness; (c) PhenoAge on macular retinal nerve fiber layer thickness; (d) DNAm-based granulocyte proportions on intraocular pressure; (e) DNAm-based plasminogen activator inhibitor-1 levels on intraocular pressure; (f) intraocular pressure on DNAm-based plasminogen activator inhibitor-1 levels.

13148_2024_1723_MOESM2_ESM.xlsx (127.6KB, xlsx)

Additional file 2: Table S1. Mendelian randomization estimations between epigenetic aging and age-related eye diseases. Table S2. Heterogeneity of Mendelian randomization estimations between epigenetic aging and age-related eye diseases. Table S3. Pleiotropy of Mendelian randomization estimations between epigenetic aging and age-related eye diseases. Table S4. Mendelian randomization estimations between age-related eye diseases and epigenetic aging. Table S5. Heterogeneity of Mendelian randomization estimations between age-related eye diseases and epigenetic aging. Table S6. Pleiotropy of Mendelian randomization estimations between age-related eye diseases and epigenetic aging. Table S7. Mendelian randomization estimations between epigenetic aging and glaucoma endophenotypes. Table S8. Heterogeneity of Mendelian randomization estimations between epigenetic aging and glaucoma endophenotypes. Table S9. Pleiotropy of Mendelian randomization estimations between epigenetic aging and glaucoma endophenotypes. Table S10. Mendelian randomization estimations between glaucoma endophenotypes and epigenetic aging. Table S11. Heterogeneity of Mendelian randomization estimations between glaucoma endophenotypes and epigenetic aging. Table S12. Pleiotropy of Mendelian randomization estimations between glaucoma endophenotypes and epigenetic aging.

Acknowledgements

We sincerely appreciate all the participants and investigators of the Edinburgh DataShare, FinnGen, International Glaucoma Genetic Consortium (IGGC), and UK Biobank groups for their valuable contribution to making statistics publicly accessible. The illustrations of diabetic retinopathy, age-related cataract, and glaucoma in Figure 1 were modified from Servier Medical Art (http://smart.servier.com/), licensed under a Creative Common Attribution 3.0 Generic License (https://creativecommons.org/licenses/by/3.0/).

Author contributions

JWC, XLY, and XCD designed the study. JWC and XYL participated in the original draft of the manuscript and literature search. JWC, XY Zhou, and JHX contributed to the formal analysis, investigation, data curation, and visualization. XY Zhou, JHX, XY Zhang, and XCD reviewed and revised the manuscript. XY Zhang and XCD contributed to project administration.

Funding

This work was supported by the Hunan Engineering Research Center for Glaucoma with Artificial Intelligence in the Diagnosis and Application of New Materials, China (Grant No. 2023TP2225 to XD), the Natural Science Foundation of Hunan Province, China (Grant No. 2023JJ70014 to XD), the Changsha Municipal Natural Science Foundation, China (Grant No. kq2208495 to XD), the Science and Technology Foundation of Aier Eye Hospital Group, China (Grant No. AR2206D5 to XD), and the Aier Glaucoma Institute. The funders played no role in the study design, data collection, data analyses, data interpretation, report writing, or decision to publish.

Availability of data and materials

The data for the four epigenetic clocks, DNA methylation proxies for granulocyte proportions, and plasminogen activator inhibitor-1 levels were available from Edinburgh DataShare (https://datashare.is.ed.ac.uk/handle/10283/3645). The summary statistics for AREDs were derived from the FinnGen study, which is available at https://www.finngen.fi/en. The summary data for glaucoma endophenotypes were obtained from the NHGRI-EBI Catalog of human genome-wide association studies (GWAS Catalog, https://www.ebi.ac.uk/gwas/).

Declarations

Conflict of interest

The authors declare no competing interests.

Ethics approval and consent to participate

Ethics approval and consent have been obtained in each original study. Since only publicly available data were used, no additional ethics approval or individual consent was required.

Consent for publication

Not applicable.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Voleti VB, Hubschman J-P. Age-related eye disease. Maturitas. 2013;75(1):29–33. 10.1016/j.maturitas.2013.01.018 [DOI] [PubMed] [Google Scholar]
  • 2.Bourne RRA, et al. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(9):e888–97. 10.1016/S2214-109X(17)30293-0 [DOI] [PubMed] [Google Scholar]
  • 3.Steinmetz JD, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144–60. 10.1016/S2214-109X(20)30489-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Becker S, et al. Modeling complex age-related eye disease. Prog Retin Eye Res. 2024;100:101247. 10.1016/j.preteyeres.2024.101247 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Jylhävä J, et al. Biological age predictors. EBioMedicine. 2017;21:29–36. 10.1016/j.ebiom.2017.03.046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Duan R, et al. Epigenetic clock: a promising biomarker and practical tool in aging. Ageing Res Rev. 2022;81:101743. 10.1016/j.arr.2022.101743 [DOI] [PubMed] [Google Scholar]
  • 7.Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115. 10.1186/gb-2013-14-10-r115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hannum G, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013;49(2):359–67. 10.1016/j.molcel.2012.10.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19(6):371–84. 10.1038/s41576-018-0004-3 [DOI] [PubMed] [Google Scholar]
  • 10.Levine ME, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018;10(4):573–91. 10.18632/aging.101414 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lu AT, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11(2):303–27. 10.18632/aging.101684 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gibson J, et al. A meta-analysis of genome-wide association studies of epigenetic age acceleration. PLoS Genet. 2019;15(11):e1008104. 10.1371/journal.pgen.1008104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1). [DOI] [PubMed]
  • 14.Emdin CA, et al. Mendelian randomization. JAMA. 2017;318(19):1925–6. 10.1001/jama.2017.17219 [DOI] [PubMed] [Google Scholar]
  • 15.Mccartney DL, et al. Genome-wide association studies identify 137 genetic loci for DNA methylation biomarkers of aging. Genome Biol. 2021;22(1):194. 10.1186/s13059-021-02398-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Martínez-Alberquilla I, et al. Neutrophils and neutrophil extracellular trap components: emerging biomarkers and therapeutic targets for age-related eye diseases. Ageing Res Rev. 2022;74:101553. 10.1016/j.arr.2021.101553 [DOI] [PubMed] [Google Scholar]
  • 17.Dan J, et al. Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma. Arch Ophthalmol. 2005;123(2):220–4. 10.1001/archopht.123.2.220 [DOI] [PubMed] [Google Scholar]
  • 18.Lambert V, et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J. 2001;15(6):1021–7. 10.1096/fsb2fj000393com [DOI] [PubMed] [Google Scholar]
  • 19.Kurki MI, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508–18. 10.1038/s41586-022-05473-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bonnemaijer PWM, et al. Multi-trait genome-wide association study identifies new loci associated with optic disc parameters. Commun Biol. 2019;2:435. 10.1038/s42003-019-0634-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Currant H, et al. Genetic variation affects morphological retinal phenotypes extracted from UK Biobank optical coherence tomography images. PLoS Genet. 2021;17(5):e1009497. 10.1371/journal.pgen.1009497 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Pan W, et al. Epigenetic age acceleration and risk of aortic valve stenosis: a bidirectional Mendelian randomization study. Clin Epigenetics. 2024;16(1):41. 10.1186/s13148-024-01647-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wang Z, et al. Effects of iron homeostasis on epigenetic age acceleration: a two-sample Mendelian randomization study. Clin Epigenetics. 2023;15(1):159. 10.1186/s13148-023-01575-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755–64. 10.1093/ije/dyr036 [DOI] [PubMed] [Google Scholar]
  • 25.Palmer TM, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res. 2012;21(3):223–42. 10.1177/0962280210394459 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Codd V, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet. 2013;45(4). [DOI] [PMC free article] [PubMed]
  • 27.Hemani G, et al. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13(11):e1007081. 10.1371/journal.pgen.1007081 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Yoshikawa M, Asaba K. Educational attainment decreases the risk of COVID-19 severity in the european population: a two-sample mendelian randomization study. Front Public Health. 2021;9:673451. 10.3389/fpubh.2021.673451 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Carter AR, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021;36(5):465–78. 10.1007/s10654-021-00757-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Greco MFD, et al. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015;34(21):2926–40. 10.1002/sim.6522 [DOI] [PubMed] [Google Scholar]
  • 31.Burgess S, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2019;4:186. 10.12688/wellcomeopenres.15555.1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Burgess S. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol. 2014;43(3):922–9. 10.1093/ije/dyu005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Hemani G, et al. The MR-base platform supports systematic causal inference across the human phenome. Elife. 2018;7. [DOI] [PMC free article] [PubMed]
  • 34.Sanderson E, et al. Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. Stat Med. 2021;40(25):5434–52. 10.1002/sim.9133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46(6):1734–9. 10.1093/ije/dyx034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Jayaram H, et al. Glaucoma: now and beyond. Lancet. 2023;402(10414):1788–801. 10.1016/S0140-6736(23)01289-8 [DOI] [PubMed] [Google Scholar]
  • 37.Tham Y-C, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90. 10.1016/j.ophtha.2014.05.013 [DOI] [PubMed] [Google Scholar]
  • 38.Chan EWE, et al. Glaucoma in Asia: regional prevalence variations and future projections. Br J Ophthalmol. 2016;100(1):78–85. 10.1136/bjophthalmol-2014-306102 [DOI] [PubMed] [Google Scholar]
  • 39.Zhang Y, et al. Aging, cellular senescence, and glaucoma. Aging Dis. 2024;15(2):546–64. 10.14336/AD.2023.0630-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Skowronska-Krawczyk D, et al. P16INK4a upregulation mediated by SIX6 defines retinal ganglion cell pathogenesis in glaucoma. Mol Cell. 2015;59(6):931–40. 10.1016/j.molcel.2015.07.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Chi W, et al. Caspase-8 promotes NLRP1/NLRP3 inflammasome activation and IL-1β production in acute glaucoma. Proc Natl Acad Sci USA. 2014;111(30):11181–6. 10.1073/pnas.1402819111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Xu Q, et al. Stress induced aging in mouse eye. Aging Cell. 2022;21(12): e13737. 10.1111/acel.13737 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Liu Y, et al. Senolytic and senomorphic agent procyanidin C1 alleviates structural and functional decline in the aged retina. Proc Natl Acad Sci USA. 2024;121(18):e2311028121. 10.1073/pnas.2311028121 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Rocha LR, et al. Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension. Aging Cell. 2020;19(2):e13089. 10.1111/acel.13089 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Mcdonnell FS, et al. Increased global DNA methylation and decreased TGFβ1 promoter methylation in glaucomatous lamina cribrosa cells. J Glaucoma. 2016;25(10):e834–42. 10.1097/IJG.0000000000000453 [DOI] [PubMed] [Google Scholar]
  • 46.Mcdonnell F, et al. Hypoxia-induced changes in DNA methylation alter RASAL1 and TGFβ1 expression in human trabecular meshwork cells. PLoS ONE. 2016;11(4):e0153354. 10.1371/journal.pone.0153354 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Cai J, et al. Differential DNA methylation patterns in human Schlemm’s canal endothelial cells with glaucoma. Mol Vis. 2020;26:483–93. [PMC free article] [PubMed] [Google Scholar]
  • 48.Wan P, et al. TET-dependent GDF7 hypomethylation impairs aqueous humor outflow and serves as a potential therapeutic target in glaucoma. Mol Ther. 2021;29(4):1639–57. 10.1016/j.ymthe.2020.12.030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Lu Y, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124–9. 10.1038/s41586-020-2975-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Chen Q, et al. Associations between the red blood cell distribution width and primary angle-closure glaucoma: a potential for disease prediction. EPMA J. 2019;10(2):185–93. 10.1007/s13167-019-00166-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Zeng H-B, et al. The inflammatory cytokine profiles and ocular biometric characteristics of primary angle-closure glaucoma. J Int Med Res. 2023;51(1):3000605221147434. 10.1177/03000605221147434 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Pan M, et al. Biomechanical correlations between the cornea and the optic nerve head. Invest Ophthalmol Vis Sci. 2024;65(5):34. 10.1167/iovs.65.5.34 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Chauhan BC, et al. Differential effects of aging in the macular retinal layers, neuroretinal rim, and peripapillary retinal nerve fiber layer. Ophthalmology. 2020;127(2):177–85. 10.1016/j.ophtha.2019.09.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Jammal AA, et al. The effect of age on increasing susceptibility to retinal nerve fiber layer loss in glaucoma. Invest Ophthalmol Vis Sci. 2020;61(13):8. 10.1167/iovs.61.13.8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Patel NB, et al. Age-associated changes in the retinal nerve fiber layer and optic nerve head. Invest Ophthalmol Vis Sci. 2014;55(8):5134–43. 10.1167/iovs.14-14303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Fleckenstein M, et al. Age-related macular degeneration: a review. JAMA. 2024;331(2):147–57. 10.1001/jama.2023.26074 [DOI] [PubMed] [Google Scholar]
  • 57.Strenk SA, et al. The mechanism of presbyopia. Prog Retin Eye Res. 2005;24(3):379–93. 10.1016/j.preteyeres.2004.11.001 [DOI] [PubMed] [Google Scholar]
  • 58.Maidana DE, et al. Peripheral monocytes and neutrophils promote photoreceptor cell death in an experimental retinal detachment model. Cell Death Dis. 2023;14(12):834. 10.1038/s41419-023-06350-6 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

13148_2024_1723_MOESM1_ESM.pdf (2.4MB, pdf)

Additional file 1: Fig. S1. Scatter plots of significant MR estimations between epigenetic age acceleration and age-related eye diseases. (a) HannumAge on primary angle-closure glaucoma; (b) intrinsic epigenetic age acceleration on primary open-angle glaucoma; (c) DNAm-based plasminogen activator inhibitor-1 levels on age-related macular degeneration; (d) DNAm-based granulocyte proportions on presbyopia; (e) DNAm-based granulocyte proportions on rhegmatogenous retinal detachment; (f) age-related cataract on HannumAge. Fig. S2. Funnel plots of significant MR estimations between epigenetic age acceleration and age-related eye diseases. (a) HannumAge on primary angle-closure glaucoma; (b) intrinsic epigenetic age acceleration on primary open-angle glaucoma; (c) DNAm-based plasminogen activator inhibitor-1 levels on age-related macular degeneration; (d) DNAm-based granulocyte proportions on presbyopia; (e) DNAm-based granulocyte proportions on rhegmatogenous retinal detachment; (f) age-related cataract on HannumAge. Fig. S3. Leave-one-out plots of significant MR estimations between epigenetic age acceleration and age-related eye diseases. (a) HannumAge on primary angle-closure glaucoma; (b) intrinsic epigenetic age acceleration on primary open-angle glaucoma; (c) DNAm-based plasminogen activator inhibitor-1 levels on age-related macular degeneration; (d) DNAm-based granulocyte proportions on presbyopia; (e) DNAm-based granulocyte proportions on rhegmatogenous retinal detachment; (f) age-related cataract on HannumAge. Fig. S4. Scatter plots of significant MR estimations between epigenetic age acceleration and glaucoma endophenotypes. (a) HannumAge on central corneal thickness; (b) intrinsic epigenetic age acceleration on central corneal thickness; (c) PhenoAge on macular retinal nerve fiber layer thickness; (d) DNAm-based granulocyte proportions on intraocular pressure; (e) DNAm-based plasminogen activator inhibitor-1 levels on intraocular pressure; (f) intraocular pressure on DNAm-based plasminogen activator inhibitor-1 levels. Fig. S5. Funnel plots of significant MR estimations between epigenetic age acceleration and glaucoma endophenotypes. (a) HannumAge on central corneal thickness; (b) intrinsic epigenetic age acceleration on central corneal thickness; (c) PhenoAge on macular retinal nerve fiber layer thickness; (d) DNAm-based granulocyte proportions on intraocular pressure; (e) DNAm-based plasminogen activator inhibitor-1 levels on intraocular pressure; (f) intraocular pressure on DNAm-based plasminogen activator inhibitor-1 levels. Fig. S6. Leave-one-out plots of significant MR estimations between epigenetic age acceleration and glaucoma endophenotypes. (a) HannumAge on central corneal thickness; (b) intrinsic epigenetic age acceleration on central corneal thickness; (c) PhenoAge on macular retinal nerve fiber layer thickness; (d) DNAm-based granulocyte proportions on intraocular pressure; (e) DNAm-based plasminogen activator inhibitor-1 levels on intraocular pressure; (f) intraocular pressure on DNAm-based plasminogen activator inhibitor-1 levels.

13148_2024_1723_MOESM2_ESM.xlsx (127.6KB, xlsx)

Additional file 2: Table S1. Mendelian randomization estimations between epigenetic aging and age-related eye diseases. Table S2. Heterogeneity of Mendelian randomization estimations between epigenetic aging and age-related eye diseases. Table S3. Pleiotropy of Mendelian randomization estimations between epigenetic aging and age-related eye diseases. Table S4. Mendelian randomization estimations between age-related eye diseases and epigenetic aging. Table S5. Heterogeneity of Mendelian randomization estimations between age-related eye diseases and epigenetic aging. Table S6. Pleiotropy of Mendelian randomization estimations between age-related eye diseases and epigenetic aging. Table S7. Mendelian randomization estimations between epigenetic aging and glaucoma endophenotypes. Table S8. Heterogeneity of Mendelian randomization estimations between epigenetic aging and glaucoma endophenotypes. Table S9. Pleiotropy of Mendelian randomization estimations between epigenetic aging and glaucoma endophenotypes. Table S10. Mendelian randomization estimations between glaucoma endophenotypes and epigenetic aging. Table S11. Heterogeneity of Mendelian randomization estimations between glaucoma endophenotypes and epigenetic aging. Table S12. Pleiotropy of Mendelian randomization estimations between glaucoma endophenotypes and epigenetic aging.

Data Availability Statement

The data for the four epigenetic clocks, DNA methylation proxies for granulocyte proportions, and plasminogen activator inhibitor-1 levels were available from Edinburgh DataShare (https://datashare.is.ed.ac.uk/handle/10283/3645). The summary statistics for AREDs were derived from the FinnGen study, which is available at https://www.finngen.fi/en. The summary data for glaucoma endophenotypes were obtained from the NHGRI-EBI Catalog of human genome-wide association studies (GWAS Catalog, https://www.ebi.ac.uk/gwas/).


Articles from Clinical Epigenetics are provided here courtesy of BMC

RESOURCES